BioSpace’s Post

USPSTF once again gives PrEP a grade A rating and importantly, extends the rating to injectable modalities. How effectively will this change the insurance landscape and ensure carriers cover injectable PrEP? Will be curious to see what implementation looks like, especially with the Braidwood decision's concurrent impact on the insurance-legal landscape for HIV prevention.

Living with HIV is a challenge in itself, and the last thing you need is additional health complications from your treatment. Truvada, an antiviral drug used in HIV treatment, is facing lawsuits due to alleged severe side effects. Here's what you should know:   #FDARecall #ProductRecalls #CoCounseling

Did you know that having another STI increases your risk of contracting HIV? Check out this article to find out more about the latest updates in STI prevention efforts: https://lnkd.in/gG6yMe3A

ESCMID 2024: Long-acting injectables for HIV prevention The implementation of PrEP throughout the European and Central Asia regions is suboptimal and varies markedly by country. - https://lnkd.in/dyp-ueJd #clinicaltrials #escmid2024 #hiv

As part of the @Chemonics International-implemented USAID Nigeria Strategic HIV/AIDS and TB Response Program (SHARP) TO1 & TO3, my colleagues and I have supported the #Nigeria government to advance strategies to #EndAIDS. Check out our recently published paper in PLOS ONE, that shares the experiences of people living with #HIV and health providers with differentiated service delivery (DSD) models for #ART treatment refills in Northern #Nigeria. Our research suggests that multi-month dispensing, and DSD models are acceptable and have the potential to improve patient retention, viral suppression, and efficiency in service delivery: https://ow.ly/Jr0350PbK9W

Preexposure Prophylaxis (PrEP) is revolutionising HIV prevention and safeguarding at-risk individuals. Dive into the details on our latest blog post! Read more on our blog below. #hiv #prep

What can the roll-out of a two-monthly HIV prevention injection learn from how the daily anti-HIV pill was introduced? Create demand, make the jab easy to get hold of and ensure it’s not stigmatised, write Wawira Nyagah and Mitchell Warren.

As part of the @Chemonics International-implemented USAID Nigeria Strategic HIV/AIDS and TB Response Program (SHARP) TO1 & TO3, my colleagues [Nnenna Ezeokafor (MPH), Bashir Zubayr, Zipporah Kpamor, Baz Semo Dessalegn MD,MPH,MSC,DTMH and I have supported the #Nigeria government to advance strategies to #EndAIDS. Check out our recently published paper in PLOS ONE, that shares the experiences of people living with #HIV and health providers with differentiated service delivery (DSD) models for #ART treatment refills in Northern #Nigeria. Our research suggests that multi-month dispensing, and DSD models are acceptable and have the potential to improve patient retention, viral suppression, and efficiency in service delivery: https://ow.ly/Jr0350PbK9W

New from JN Learning: USPSTF Review: Preexposure Prophylaxis for the Prevention of HIV https://lnkd.in/gqykS7CQ

ASCP Daily Diagnosis 08/17 CST Doravirine plus lamivudine and tenofovir disoproxil fumarate (DOR/3TC/TDF) is a well-tolerated option for nonoccupational HIV postexposure prophylaxis (PEP). Our study sheds light on PEP use in men who have sex with men (MSM )populations, predominantly observed in larger cities within affluent nations. https://lnkd.in/g7PUxq28